Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2017 (2017), Article ID 6971027, 5 pages
https://doi.org/10.1155/2017/6971027
Case Report

A Case of Rituximab-Induced Necrotizing Fasciitis and a Review of the Literature

1Department of Medicine, Reading Hospital, West Reading, PA, USA
2Department of Anesthesiology, Mayo Clinic Hospital, Rochester, MN, USA

Correspondence should be addressed to Abdullateef Abdulkareem; gro.htlaehgnidaer@meerakludba.oyad

Received 13 July 2017; Accepted 22 August 2017; Published 26 September 2017

Academic Editor: Marie-Christine Kyrtsonis

Copyright © 2017 Abdullateef Abdulkareem et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. S. Kotrappa, R. S. Bansal, and N. M. Amin, “Necrotizing fasciitis,” American Family Physician, vol. 53, no. 5, pp. 1691–1696, 1996. View at Google Scholar · View at Scopus
  2. T. W. Hakkarainen, N. M. Kopari, T. N. Pham, and H. L. Evans, “Necrotizing soft tissue infections: review and current concepts in treatment, systems of care, and outcomes,” Current Problems in Surgery, vol. 51, no. 8, pp. 344–362, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. B. J. Childers, L. D. Potyondy, R. Nachreiner et al., “Necrotizing fasciitis: a fourteen-year retrospective study of 163 consecutive patients,” The American Journal of Surgery, vol. 68, pp. 109–116, 2002. View at Google Scholar
  4. M. Y. Mok, S. Y. Wong, T. M. Chan, W. M. Tang, W. S. Wong, and C. S. Lau, “Necrotizing fasciitis in rheumatic diseases,” Lupus, vol. 15, no. 6, pp. 380–383, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Fang, W. Xu, and J.-Y. Li, “A systematic review and meta-analysis of rituximab-based immunochemotherapy for subtypes of diffuse large B cell lymphoma,” Annals of Hematology, vol. 89, no. 11, pp. 1107–1113, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Gao, X. Liang, J. Jiang et al., “A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma,” Acta Oncologica, pp. 1–11. View at Publisher · View at Google Scholar
  7. B. H. Rovin, R. Furie, K. Latinis et al., “Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab Study.,” Arthritis and rheumatism, vol. 64, no. 4, pp. 1215–1226, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Emery, A. Deodhar, and W. F. Rigby, “Efficacy and safety of different doses and retreatment of rituximab: A randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)) (Annals of the Rheumatic Diseases (2010) 69, (1629-1635)),” Annals of the Rheumatic Diseases, vol. 70, no. 8, p. 1519, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Lazzeri, T. Agostini, M. Figus, M. Nardi, M. Pantaloni, and S. Lazzeri, “More on periorbital infections following therapy with biological agents,” Cutaneous and Ocular Toxicology, vol. 30, no. 4, pp. 338-339, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Lazzeri, S. Lazzeri, M. Figus et al., “Periorbital necrotising fasciitis,” British Journal of Ophthalmology, vol. 94, no. 12, pp. 1577–1585, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. D. M. Guerrero, F. Perez, N. G. Conger et al., “Acinetobacter baumannii-associated skin and soft tissue infections: recognizing a broadening spectrum of disease,” Surgical Infections, vol. 11, no. 1, pp. 49–57, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Wong, H. Chang, S. Pasupathy, L. Khin, J. Tan, and C. Low, “Necrotizing fasciitis,” The Journal of Bone and Joint Surgery-American Volume, vol. 85, no. 8, pp. 1454–1460, 2003. View at Publisher · View at Google Scholar
  13. J. A. Krieger, J. M. Merin, and I. Rabinowitz, “Necrotizing fasciitis following rituximab therapy,” Journal of Oncology Pharmacy Practice, vol. 8, no. 4, pp. 127–129, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. R. J. Looney, J. H. Anolik, D. Campbell et al., “B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab,” Arthritis and Rheumatism, vol. 50, no. 8, pp. 2580–2589, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. T. Chen and D. Isenberg, “Necrotizing fasciitis in systemic lupus erythematosus: a case report and literature review,” in Lupus science & medicine, vol. 1, p. 10, DOI, 10.1136/lupus-2014-000008, 2014. View at Google Scholar
  16. T. Morita, T. Ugai, T. Tanimoto, and K. Matsue, “Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenström macroglobulinaemia,” BMJ case reports, vol. 2014, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Raghuvanshi and A. Menon, “A fulminant case of necrotising fasciitis secondary to rituximab in a patient with rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 71, no. Suppl 3, pp. 671.7–671, 2014. View at Publisher · View at Google Scholar
  18. D. A. Anaya and E. P. Dellinger, “Necrotizing soft-tissue infection: diagnosis and management,” Clinical Infectious Diseases, vol. 44, no. 5, pp. 705–710, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. J.-E. Gottenberg, P. Ravaud, T. Bardin et al., “Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry,” Arthritis and Rheumatism, vol. 62, no. 9, pp. 2625–2632, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. B. Terrier, Z. Amoura, P. Ravaud et al., “Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French autoimmunity and rituximab registry,” Arthritis and Rheumatism, vol. 62, no. 8, pp. 2458–2466, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Lanini, A. C. Molloy, P. E. Fine, A. G. Prentice, G. Ippolito, and C. C. Kibbler, “Risk of infection in patients with lymphoma receiving rituximab: Systematic review and meta-analysis,” BMC Medicine, vol. 9, article no. 36, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Salliot, M. Dougados, and L. Gossec, “Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: Meta-analyses of randomised placebo-controlled trials,” Annals of the Rheumatic Diseases, vol. 68, no. 1, pp. 25–32, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. Ö. Ekiz, B. B. Şen, E. N. Rifaioǧlu, T. Özgür, M. U. Inan, and Ç. A. Doǧramaci, “Necrotizing fasciitis in a patient with bullous pemphigoid treating with systemic steroid,” Cutaneous and Ocular Toxicology, vol. 32, no. 3, pp. 252–254, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. A. T. Y. Chan, V. Cleeve, and T. J. Daymond, “Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis,” Postgraduate Medical Journal, vol. 78, no. 915, pp. 47-48, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Souyri, “Severe necrotizing soft-tissue infections and nonsteroidal anti-inflammatory drugs,” Clinical and Experimental Dermatology, vol. 33, no. 3, pp. 249–55, 2008. View at Publisher · View at Google Scholar
  26. N. Hashimoto, T. Yamaoka, H. Koguchi-Yoshioka et al., “Development of necrotising fasciitis in a patient treated for rheumatoid arthritis with tocilizumab,” Acta Dermato-Venereologica, vol. 95, no. 3, pp. 370-371, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Rosser, G. Swallow, R. A. Swann, and C. Chapman, “Salmonella enteritidis necrotising fasciitis in a multiple myeloma patient receiving bortezomib,” International Journal of Hematology, vol. 91, no. 1, pp. 149–151, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. N.-C. Cheng, Y.-C. Yu, H.-C. Tai et al., “Recent trend of necrotizing fasciitis in taiwan: Focus on monomicrobial Klebsiella pneumoniae necrotizing fasciitis,” Clinical Infectious Diseases, vol. 55, no. 7, pp. 930–939, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. D. Yahav, H. Duskin-Bitan, N. Eliakim-Raz et al., “Monomicrobial necrotizing fasciitis in a single center: The emergence of Gram-negative bacteria as a common pathogen,” International Journal of Infectious Diseases, vol. 28, pp. 13–16, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. I. Srivastava et al., “Spontaneous C. septicum gas gangrene: a literature review,” Anaerobe, 2017. View at Google Scholar
  31. C.-Y. Lee, L.-T. Kuo, K.-T. Peng, W.-H. Hsu, T.-W. Huang, and Y.-C. Chou, “Prognostic factors and monomicrobial necrotizing fasciitis: gram-positive versus gram-negative pathogens,” BMC Infectious Diseases, vol. 11, article 5, 2011. View at Publisher · View at Google Scholar · View at Scopus